AI주식인사이트AI Stock Insight
B

제넥신

095700KOSDAQ

56.0 / 100

Reference Date: 2026-10-23

Financial Score23.5 / 40
News Sentiment12.5 / 25
Momentum8.0 / 20
Disclosure12.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 11.4% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Genexine focuses on developing innovative therapies for cancer and immune-related diseases using its proprietary bioPROTAC technology, which leverages biologics like nanobodies to overcome limitations of traditional small-molecule-based PROTAC approaches. The company aims to effectively degrade target proteins by utilizing advanced targeted protein degradation techniques, enabling precise and efficient disease treatment.

Number of Employees

68people

Average Salary

82.7M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
0.46Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE
-10.71Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
3.10Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20254.5 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲11.1% (2-year basis)

Operating Profit Growth Rate
2.0 / 3

Avg ▲6.3% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -18.9% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (5%, downtrend)

Current 2,485Won52-week high 7,10052-week low 2,195
1-month return1.0Point

1m -11.41% (falling)

Volume trend6.0Point

Volume surge

Detailed Disclosure

4 totalPositive 1Neutral 3Negative 0
  • Positive주요사항보고서(유상증자결정)2026-10-16
  • Neutral소액공모공시서류(지분증권)2026-10-16
  • Neutral주주총회소집결의 (임시주주총회)2026-10-06
  • Neutral주주명부폐쇄기간또는기준일설정2026-10-06